血浆制品中人细小病毒B19的灭活／去除研究进展  

The progress in research of the inactivation/removal of human parvovirus B19 in plasma-derived products

作　　者：卜凤荣(综述)[1] 于军(综述)[2] 宿艳笋(综述)[1] 

机构地区：[1]河北医科大学科技总公司河北大安制药有限公司研发部,石家庄050018 [2]河北医科大学科技总公司供应部,石家庄050018

出　　处：《国际生物制品学杂志》2009年第6期320-323,共4页International Journal of Biologicals

摘　　要：存在于血浆制品中的人细小病毒B19（human parvovirusB19，B19）是传播B19的潜在危险，尤其是B19可经污染的血浆制品的输注而在易感人群中传播。据认为，B19对普通的理化灭活方法有较强的抵抗力。然而，各项研究显示，B19对加热和低pH处理较敏感。因此，可以选择合适的方法来灭活B19。The presence of human parvovirus B19 （B19） in plasma-derived products indicates a potential risk of B19 transmission, and especially, B19 may be transmitted by transfusion of the contaminated plasma and plasma-derived products in susceptible individuals. It is believed that B19 is more resistant to common physieochemical inactivation methods. However, the various studies show that B19 is more sensitive to heat and low pH treatment. So suitable methods may be selected to inactivate B19.

关 键 词：细小病毒B19 人 生物制品 病毒灭活 

分 类 号：R373[医药卫生—病原生物学] R457.1[医药卫生—基础医学]